Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  PRA Health Sciences, Inc.    PRAH

PRA HEALTH SCIENCES, INC.

(PRAH)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/21/2021 01/22/2021 01/25/2021 01/26/2021 01/27/2021 Date
134.66(c) 132.26(c) 131.38(c) 128.17(c) 121.86 Last
228 145 342 212 429 963 290 748 279 841 Volume
-1.37% -1.78% -0.67% -2.44% -4.92% Change
More quotes
Financials (USD)
Sales 2020 3 138 M - -
Net income 2020 227 M - -
Net Debt 2020 918 M - -
P/E ratio 2020 36,5x
Yield 2020 -
Sales 2021 3 493 M - -
Net income 2021 288 M - -
Net Debt 2021 638 M - -
P/E ratio 2021 29,0x
Yield 2021 -
Capitalization 7 817 M 7 817 M -
EV / Sales 2020 2,78x
EV / Sales 2021 2,42x
Nbr of Employees 17 500
Free-Float 99,8%
More Financials
Company
PRA Health Sciences, Inc. is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases. Its services include data management, statistical analysis, clinical trial... 
More about the company
Notations Surperformance© of PRA Health Sciences, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about PRA HEALTH SCIENCES, INC.
01/11INSIDER TRENDS : Insider Adds to Selling Trend at PRA Health Sciences
MT
01/07PRA HEALTH SCIENCES : UBS Adjusts Price Target on PRA Health Sciences to $128 Fr..
MT
2020PRA HEALTH SCIENCES, INC. : Entry into a Material Definitive Agreement, Creation..
AQ
2020PRA HEALTH SCIENCES : Teams Up With PWNHealth, Fulgent Genetics To Provide At-Ho..
MT
2020PRA Health Sciences collaborates with PWNHealth and Fulgent Genetics to provi..
GL
2020Appili Therapeutics Says First Patient Dosed in Phase 3 Clinical Trial of Tab..
MT
2020PRA HEALTH SCIENCES : appoints senior FDA official to lead new Global Center of ..
AQ
2020PRA HEALTH SCIENCES : appoints senior FDA official to lead new Global Center of ..
AQ
2020PRA Health Sciences appoints senior FDA official to lead new Global Center of..
GL
2020PRA HEALTH SCIENCES : Management's Discussion and Analysis of Financial Conditio..
AQ
2020Credit Suisse Adjusts PRA Health Sciences' Price Target to $125 From $120, Ma..
MT
2020PRA HEALTH SCIENCES : Q3 2020 Earnings Presentation
PU
2020PRA HEALTH SCIENCES : 3Q Earnings Snapshot
AQ
2020PRA Health Sciences Q3 Surpasses Street Estimates, Guidance Ahead
MT
2020PRA HEALTH SCIENCES, INC. : Results of Operations and Financial Condition, Finan..
AQ
More news
News in other languages on PRA HEALTH SCIENCES, INC.
2020PRA Health Sciences ernennt hochrangigen FDA-Beamten zum Leiter des neuen Glo..
2020PRA Health Sciences von BARDA als Mitglied des exklusiven Clinical Studies Ne..
2020PRA Health Sciences et Deep Lens annoncent une relation stratégique afin d'ac..
2020PRA Health Sciences annonce la nomination d'un nouveau directeur
2018PRA HEALTH SCIENCES : erhält Auszeichnung als internationales klinisches Forschu..
More news
Analyst Recommendations on PRA HEALTH SCIENCES, INC.
More recommendations
Chart PRA HEALTH SCIENCES, INC.
Duration : Period :
PRA Health Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PRA HEALTH SCIENCES, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 124,75 $
Last Close Price 128,17 $
Spread / Highest target 13,1%
Spread / Average Target -2,67%
Spread / Lowest Target -34,5%
EPS Revisions
Managers and Directors
NameTitle
Colin Shannon Chairman, President & Chief Executive Officer
Michael J. Bonello Chief Financial Officer & Executive Vice President
Kent Thoelke Chief Scientific Officer & Executive VP
Isaac Rodriguez-Chavez Senior VP-Scientific & Clinical Affairs
Jeffrey T. Barber Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PRA HEALTH SCIENCES, INC.2.18%8 222
MODERNA, INC.45.35%60 120
LONZA GROUP AG5.49%50 227
CELLTRION, INC.-10.58%39 891
IQVIA HOLDINGS INC.0.65%34 576
SEAGEN INC.-1.43%31 230